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S U M M A R Y
Objective: To understand the pattern of immune responses to pneumococcal proteins during invasive
disease as a guide to their development as vaccine candidates.
Methods: The antibody concentration and avidity, as well as frequency of interferon-gamma (IFN-g)-,
interleukin-10 (IL-10)-, and tumor necrosis factor-alpha (TNF-a)-containing CD4+ T-lymphocytes in
response to pneumolysin, pneumococcal surface protein A (PspA), and choline-binding protein A (CbpA),
during and after invasive pneumococcal disease (IPD) in 20 children were compared to those of 20
healthy matched controls.
Results: During the acute phase of IPD, the concentrations of antibodies against these three
pneumococcal proteins were lower, whereas the frequencies of IL-10- and TNF-a-producing CD4+ T-
cells were higher, compared to values obtained during convalescence and in healthy controls (p< 0.01).
In addition, the concentrations of antibodies against the capsular polysaccharides for the serotypes
isolated from these patients, were all below the detection level of the assay during both the acute and
convalescent phases of IPD.
Conclusion: These data indicate that the recognition of these antigens by the immune system occurs in
variable proportions according to the stage of infection, implying the important role of these in the
pathogenesis of IPD, and support their usefulness in vaccine development.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Streptococcus pneumoniae is one of the major causes of
respiratory tract infections and invasive diseases in children
worldwide.1,2 Approximately 1 million children under 5 years of
age die annually of pneumococcal diseases, and most of these
occur in sub-Saharan Africa.3,4 The high prevalence of invasive
disease in developing countries is assumed to be a reﬂection of the
high rate of nasopharyngeal carriage.5–7 Nasopharyngeal coloni-
zation with pneumococci occurs in 20–50% of young children in
Western Europe,8 but can be as high as 90% in children aged <5
years in sub-Saharan Africa.6,9
Antibody responses to the polysaccharide antigens play amajor
role in immunity to pneumococcal diseases. The antibodies* Corresponding author. Tel.: +220 4494482; fax: +220 4495919.
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doi:10.1016/j.ijid.2010.12.011induced by pneumococcal conjugate vaccines are effective in
protecting against nasopharyngeal carriage and invasive pneumo-
coccal diseases (IPD) by serotypes contained within the vac-
cine.10,11 However, the use of conjugate vaccines for protection
against IPD is limited not only by their serotype coverage (which
varies in different settings), but also by the potential for serotype
replacement, and the cost and complexity of production.12 These
issues have led to the consideration of the development of a non-
serotype-dependent pneumococcal vaccine.13 In this regard,
pneumococcal proteins and protein–polysaccharide components
are promising for use in vaccines, as they have the potential to be
inexpensive, immunogenic in young children, and most likely
effective against all serotypes. In addition, pneumococcal protein
antigens induce T-lymphocyte responses, which contribute to
protection against both nasopharyngeal carriage and IPD.14 Some
of the protein candidates being considered include pneumolysin,
pneumococcal surface protein A (PspA), and choline-binding
protein A (CbpA).15–17 However, their role in IPD in humans isses. Published by Elsevier Ltd. All rights reserved.
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immune responses to pneumolysin, PspA, and CbpA during and
after IPD in order to identify factors contributing to increased
vulnerability to IPD, and to determine if the disease process
induces changes in the immune responses considered.
2. Methods
2.1. Study site and recruitment of study participants
Subjects were recruited as part of formal surveillance for
invasive bacterial disease in children in theWestern Region of The
Gambia. Acutely ill febrile children aged 0–9 years admitted to the
pediatricward of the Royal Victoria TeachingHospital, Banjul, The
Gambia were investigated by culture of cerebrospinal ﬂuid (CSF)
or blood or both. This study was conducted between 2007 and
2009 when the pneumococcal vaccine had not yet been
introduced into the national immunization schedule. Those with
positive cultures were considered as cases of IPD and were
consecutively recruited into this study after written informed
consent had been obtained from the parent/caregiver. Healthy
children of the same age from a nearby health centre were
recruited as controls after parental/caregiver consent was
obtained. The study was approved by the joint Gambia Govern-
ment/MRC Ethics Committee (SCC L2007.53).
Isolation of S. pneumoniae from the CSF and venous blood
samples was done according to standard procedures, as previously
described.6 Serotype was determined by latex agglutination using
serotype-speciﬁc antisera, while isolates with equivocal results
were conﬁrmed by the Quellung reaction.
2.2. Blood sampling
On admission, 2 ml of venous blood was obtained as soon as
IPD was conﬁrmed (acute sample). Appropriate antibiotic and
supportive treatments were completed and patients discharged
with an instruction to come back to the clinic at 4 weeks after
the start of treatment. At this follow-up visit, the child was
examined for general well-being as well as for any neurological
deﬁcit. Thereafter another venous blood sample (convalescent
sample) was obtained. The acute and convalescent blood
samples were processed within 6 h of collection. A venous
blood sample (2 ml) was obtained from healthy children of the
same age attending the well-child clinic at the Sukuta Health
Centre (controls).
2.3. Antigens and overnight antigenic stimulation
Recombinant pneumolysin (Ply), CbpA, and PspA were pre-
pared and used as previously described.18 Pneumococcal culture
supernatant was prepared from a standard encapsulated type 2
(D39) S. pneumoniae strain (WT). The protein content of the
concentrated pneumococcal culture supernatant was determined
using the Bio-Rad protein assay (Bio-Rad, UK).
Venous blood samples were collected in heparinized tubes;
serum was separated and stored at 70 8C until analysis. The
remaining blood sample was resuspended 1:1 in RPMI culture
medium, from which 200 ml was taken per stimulation in a
polypropylene tube (BD Pharmingen, USA). Blood was cultured
overnight with WT (5mg/ml), Ply (5mg/ml), phytohemagglutinin
(PHA; 5mg/ml) and puriﬁed protein derivative (PPD RT49; SSI,
Denmark; 10 mg/ml) were used as positive controls while culture
medium alone was the negative control, and processed as
previously described .19 Tubes were vortexed, covered, and
maintained at 37 8C, 5% CO2 overnight (16 h). Brefeldin A (Sigma)
was added after 2 h (ﬁnal concentration 10 mg/ml).2.4. Whole blood intracellular cytokine staining
Following overnight stimulation, 20 ml of previously titrated
surface marker cocktail (CD4-PerCP and CD8-Paciﬁc Blue; both
from BD Biosciences, USA) was added to each tube, as previously
described.19 Tubes were then vortexed and incubated for 30 min at
room temperature (RT). Two milliliters of FACS lysing solution (BD
Pharmingen, USA) was added and the tubes vortexed and
incubated for 9 min at RT in the dark, followed by centrifugation
for 5 min at 1500 rpm at RT. Following removal of the supernatant,
500ml of 1 FACS Perm2 solution (BD Pharmingen, USA) was
added and the tubes vortexed and incubated for 20 min at RT in the
dark. Following centrifugation (1800 rpm, RT, 5 min), the super-
natant was carefully removed and 20ml of cytokine cocktail
(interferon-gamma (IFN-g)–allophycocyanin (APC), tumor necro-
sis factor-alpha (TNF-a)–ﬂuorescein isothiocyanate (FITC), and
interleukin-10 (IL-10)–phycoerythrin (PE); all from BD Pharmin-
gen, USA) was added. Tubes were again vortexed and incubated for
30 min at RT in the dark. Tubeswere thenwashed by adding 1 ml of
FACS buffer (phosphate-buffered saline (PBS)/1% fetal calf serum
(FCS)/0.02% sodium azide (Az)) and centrifuged at 1800 rpm for
5 min. Finally, the supernatantwas removed and cells resuspended
in 1% paraformaldehyde (PFA) for acquisition.
2.5. Flow cytometry analysis
All samples were processed with a CyAn ADPTM (Beckman
Coulter, USA) ﬂow cytometer following gating on lymphocytes
according to 908 forward and side-scatter plots. FACS plots were
analyzed using FlowJo software version 6.1.1 (Treestar; Ashland,
OR, USA). The proportion of cells producing each cytokine was
calculated within the total population of CD4+ or CD8+ T-cells and
background subtracted (as determined from the medium-alone
negative control).
2.6. Serological determinations
2.6.1. Measurement of anti-pneumococcal IgG
ELISA was used to measure immunoglobulin type G (IgG)
antibodies against speciﬁc pneumococcal proteins. Microtiter
plates (CoStar, USA) were coated overnight at 4 8C with Ply
(2mg/ml), CbpA (5mg/ml), or PspA (5mg/ml) in PBS. Plates were
then washed with PBS 0.1% Tween 20 (ELISA wash buffer), blocked
with 10% fetal calf serum (FCS) in PBS (blocking buffer) for 2 h at RT
and washed (two times); serum samples (1/10 and 1/100 dilutions
with blocking buffer) were added to the wells. Sandoglobulin
(Sandoz UK, kindly provided by David Goldblatt), which contains
high IgG antibody titers to Ply, PspA, and CbpA, was used as the
standard, starting with a 1/500 dilution that was assigned an
antibody titer of 1000 U/ml, for each of the protein antigens. Serum
samples and standardwere added in duplicatewells and incubated
for 90 min on a horizontal shaker (150 rpm) at RT. Following
washing, the plates were incubated with alkaline phosphatase-
conjugated goat anti-human IgG for 90 min on a horizontal shaker
at RT. They were then washed and the color developed by
incubating with p-nitrophenyl phosphatase in substrate buffer in
the dark for 30 min at RT. Absorbance was read at 405 nm on an
ELISA reader (Multiscan, Labsystems, Finland) and analyzed using
Softmax Pro software (Molecular Devices, Sunnyvale, CA, USA).
The concentrations of IgG antibodies to pneumococcal capsular
polysaccharides 5, 6B, and 14 were measured from sera taken
during the acute and convalescent phases of IPD, as previously
described.10 The antibody titers to other serotypes isolated from
the IPD patients are not routinely done in our laboratory. The titers
were expressed in mg/ml after calculation with reference to
assigned values of IgG in the 89-SF reference serum. The lower
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tested, apart from serotype 14 for which it was 0.002mg/ml.
2.6.2. Measurement of anti-pneumococcal IgG avidity
Plates were coated and blocked as stated above, and each 1/100
dilution of serum and 1/8000 dilutions of standardwere added into
six duplicate wells and incubated for 2 h on a horizontal shaker
(150 rpm) at RT. After washing, sodium thiocyanate in blocking
buffer (NaSCN; Sigma, St. Louis, MO, USA) was used to dissociate
antibody–antigen complexes. To get a high resolution of antibodies
with different avidities, the concentration of NaSCN was titrated.
For each sample, control (blocking buffer, 0 M), and a series of ﬁve
different concentrations of NaSCN (4, 2, 1, 0.5, and 0.1 M solutions)
were added into a pair of wells containing the samples or standard
for 15 min, and immediately washed four times with the wash
buffer. Thereafter, the remaining steps of the procedure were
essentially as done for antibodymeasurement above. As ameasure
of the avidity of IgD antibodies present in the serum samples, the
avidity index (AI) was used. AI was calculated as the percentage of
the antibodies that remained bound after NaSCN treatment. It was
calculated by dividing the endpoint titer of the serum sample with
NaSCN treatment by the end-point titer of the sample without
NaSCN treatmentmultiplied by 100. Reproducibility of themethod
was ensured by including a control serum on each plate.
2.7. Statistical analysis
Comparisons of cases (acute or convalescent stages) to healthy
controls were conducted using the Wilcoxon rank sum test, due to
non-normal distribution of the data. Comparisons of acute versus
convalescent data were carried out using paired t-tests if the
distribution of differences was normal or the Wilcoxon matched
pairs signed rank test if the distribution of differences was non-
normal. Analyses were done using STATA release 10 statistical
software (Stata Corp., College Station, TX, USA).
3. Results
Twenty children, 14 boys and6 girls,were identiﬁed as having IPD
within the studyperiod. S. pneumoniaewas isolated fromtheCSF in all
of them, and also fromblood in four of them. Ten of the S. pneumoniae
isolates were subjected to serotyping, which showed that ﬁve wereTable 1
Pneumococcal anti-capsular antibody titers to the serotypes isolated from children
with invasive pneumococcal disease (IPD)a
Patient ID Serotype
isolated
Acute serotype
anti-capsular
antibody (mg/ml)
Convalescent serotype
anti-capsular
antibody (mg/ml)
PC-040 10A ND ND
PC-042 14 <0.002 0.001
PC-048 14 <0.002 NA
PC-054 5 <0.001 0.001
PC-076 35B ND ND
PC-077 14 <0.002 0.001
PC-080 6B <0.001 NA
PC-087 14 <0.002 NA
PC-088 14 <0.002 NA
PC-096 9V 0.07 NA
ND, not done; NA, not available.
a Pneumococcal anti-capsular antibody titers in serum against the serotypes
isolated from each patient during acute and convalescent phases of IPD. Antibody
against the capsular antigen to the serotype isolated from the CSF of these patients
was measured in the corresponding serum obtained during the acute and
convalescent phases of IPD as previously described. The titers are expressed in
mg/ml after calculation with reference to assigned values of IgG in the 89-SF
reference serum. The lower limit of detection of the assay was 0.001mg/ml for the
serotypes tested, apart from serotype 14 for which it was 0.002mg/ml.serotype 14, while one each were serotypes 5, 6B, 9 V, 10A, and 35B
(Table 1). One child was HIV-1-seropositive. Their age ranged from 1
monthto6years. Fourchildren(allwithmeningitis alone)diedduring
the hospital admission and another ﬁve subjects did not come for the
follow-up visit. Therefore nine cases did not have convalescent blood
samples available for analysis. Therewasanequal ratioof boys togirls
in the control group and these were similar to the cases in age and
ethnicity, as well as place of domicile.
3.1. Serological responses
During the acute phase of IPD the median (interquartile range
(IQR)) antibody concentrations (U/ml) were: 199 (145–306) to Ply,Acute Conv Control
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Figure 1. Comparison of antibody levels during acute and convalescent phases of
invasive pneumococcal disease (IPD). Antibody against pneumolysin (Ply) (A),
pneumococcal surface protein A (PspA) (B), and choline-binding protein A (CbpA)
(C) was assessed by ELISA in subjects with acute IPD (n = 20) and compared to the
same subjects in the convalescent phase (Conv; n = 11) and healthy controls
(n = 20). The horizontal lines indicate the median and the p-values indicate
signiﬁcant differences between the groups.
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signiﬁcantly lower compared to the healthy controls (Ply 369
(206–662), PspA 366 (280–460), and CbpA 703 (504–904))
(Figure 1). The median (IQR) antibody concentrations during the
convalescent phase were: 366 (227–455) to Ply, 253 (115–378) to
PspA, and 279 (164–413) to CbpA; thesewere also generally higher
compared to the values obtained in the acute phase, with those of
Ply and CbpA being signiﬁcantly higher (p = 0.006 and 0.022,
respectively; Figure 1, A and C). The median antibody concentra-
tions in the convalescent phase of the disease still tended to be
lower than the concentrations observed in the healthy control
children, but only that of CbpA was signiﬁcantly lower (p < 0.001;Acute
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Figure 2. Comparison of antibody avidity indices during acute and convalescent
phases of invasive pneumococcal disease (IPD). The avidity index of antibody to
pneumolysin (Ply) (A), pneumococcal surface protein A (PspA) (B), and choline-
binding protein A (CbpA) (C) was assessed by ELISA in subjects with acute IPD (n =
20) and compared to the same subjects in the convalescent phase (Conv; n = 11) and
healthy controls (n = 20). The horizontal lines indicate medians and the p-values
indicate signiﬁcant differences between the groups.Figure 1C). The anti-capsular antibody levels to the speciﬁc
serotype isolated from each patient were below the detection
limits for the assay, and consequently below the protective level of
0.35mg/ml, in both the acute and convalescent phases of the
disease (Table 1).
The avidity of the antibodies to the three pneumococcal
proteins during the acute phase was lower than that in the
convalescent phase of the disease, but the differences were not
statistically signiﬁcant (Figure 2). Unlike the antibody concentra-
tions measured during the acute and convalescent phases of the
disease, the antibody avidity in the convalescent phase was
signiﬁcantly higher than that of the control group for PspA (p =
0.039) and CbpA (p = 0.021), but not for Ply (Figure 2).
3.2. T-cell responses during and after IPDweremainly from CD4+ cells
The cellular immune responses were evaluated by measuring
the frequency of CD4+ and CD8+ T-cells that expressed IFN-g, IL-
10, or TNF-a, by ﬂow cytometry following overnight stimulation
with pneumococcal antigens. Following lymphocyte gating, cells
were then analyzed for percent CD4+ and CD8+ cells expressing
any of the three cytokines (Figure 3A).We noted that the responses
were mainly from CD4+ T-cells in both the acute and convalescent
phases of the illness, but there was very low production in the
acute phase (Figure 3B, top panel), which was restored to all
antigens in the convalescent phase (Figure 3B, bottom panel).
There was no signiﬁcant difference in the frequency of IFN-g-
expressing CD4+ T-cells between the acute and convalescent
phases following stimulation with both pneumococcal and control
antigens (Figure 4, A, D, and G). The median (IQR) percentage of IL-
10-expressing CD4+ T-cells in the acute phase following stimula-
tion with WT (0.3 (0.27–0.70)) and Ply (0.28 (0.19–0.385)), were
signiﬁcantly higher compared to the frequencies observed in the
healthy control children: 0.12 (0.06–0.20) and 0.13 (0.05–0.23),
respectively (p = 0.001 for both; Figure 4, B and E). The frequencies
were also signiﬁcantly higher during the acute phase compared to
the convalescent phase with 0.11 (0.03–0.31) and 0.12 (0.06–0.23)
percentage of CD4+ IL-10+ cells in response to WT and Ply
stimulation, respectively (p = 0.014 and 0.012, respectively;
Figure 4, B and E). The IL-10 levels were comparable to those
seen in the healthy controls in the convalescent phase (Figure 4, B
and E). Similarly, themedian proportion of CD4+ T-cells expressing
TNF-a during the acute phase was signiﬁcantly higher compared
to the convalescent phase after stimulation with Ply (0.24 (0.06–
0.52) vs. 0.08 (0.026–0.26); p = 0.015) and WT (0.4 (0.28–1.35) vs.
0.07 (0.01–0.44); p = 0.01) (Figure 4, C and F). Proportions of CD4+
TNF-a+ cells during the acute phase were also signiﬁcantly higher
than in the healthy controls (p = 0.001 for both; Figure 4, C and F).
In contrast, there was no difference in the frequency of CD4+ T-
cells expressing any of these three cytokines in response to PHA
stimulation for any of the groups (Figure 4, G, H, and I).
4. Discussion
Our data show that Ply, PspA, and CbpA pneumococcal proteins
induce antibody and T-cell responses in children in The Gambia.
The concentrations of antibodies to the pneumococcal proteins
evaluated were low during the acute phase of IPD as compared to
the levels during convalescence and in healthy controls. These
antibody levels increased during the convalescent phase, but were
still somewhat lower than in the healthy controls. In contrast to the
antibody levels, the avidity was higher during the acute and
convalescent phases as compared to the controls, particularly for
PspA and CbpA. The acute phase of the disease was characterized
by signiﬁcantly higher frequencies of IL-10- and TNF-a-producing
Figure 3. Intracellular cytokine analysis during acute and convalescent phases of invasive pneumococcal disease (IPD). Representative ﬂow cytometry dot plots showing that
responses to pneumococcal antigens weremainly from CD4+ T-cells (A). CD4+ responses to phytohemagglutinin (PHA), puriﬁed protein derivative (PPD), pneumolysin (Ply),
and standard encapsulated type 2 (D39) S. pneumoniae strain (WT) antigens were determined following overnight stimulation of whole blood. Representative ﬂow cytometry
dot plots show very low responses to all antigens in the acute phase of the infection and restoration during the convalescent (Conv) phase.
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healthy controls in the convalescent phase.
We have demonstrated that the antibody concentration to the
threepneumococcal proteinswas lowerduring the acutephaseof IPD
as compared to the convalescent phase and in healthy controls. The
serotype anti-capsular polysaccharide antibody titers were also
below the detection limit of the assay and the protective level for
invasive disease. The host defense against S. pneumoniae depends
largelyon thebindingofantibodiesandcomplement to thesurfacesof
the pathogen.20,21 Although the protective titers to pneumococcal
proteinsareyet tobedetermined,ourdatasupport therequirementof
antibodies to these pneumococcal proteins for protection against IPD.
While antibody titers are indicators of the magnitude of response,
avidity is an index of functionality, and increases with secondary
exposure to an antigen.22,23 Avidity indices at low antibody titers are
usually unreliable, such as those measured during the acute phase of
IPD when the antibody titers were low. However, the difference in
avidity observed between the convalescent phase and the healthy
controlswith comparable antibody titers is reliable. Thus, our ﬁnding
of relatively higher antibody avidity to these proteins after IPD
compared to healthy controls suggests a response to exposure to the
pneumococcus, and further underlines the fact that the absolute
concentration of the antibody is important to curtail the infection.
Similarly, high antibody levels to Ply and CbpA have been shown to
protect against nasopharyngeal carriage of pneumococcus and
probably IPD.11 A study in Finnish children also showed that lower
antibody titers to PspA predisposed to IPD.24 Subjects colonized by S.
pneumoniae have also been observed to have higher serum IgG
concentrations to Ply compared to patients with pneumococcal
bacteremia.25 The persistently low antibody concentration during
convalescence compared to the healthy controls could also suggest
the existence of an intrinsic defect in the production of antibodies tothese proteins. It is expected that large amounts of pneumococcal
protein antigens expressed in the host during IPD would induce
signiﬁcantly higher antibody responses as compared to healthy
controls whose antibodies are most likely produced following
colonization by pneumococcus in the nasopharynx.26 Thus the
relatively lower concentrations during convalescence, particularly in
the face of increasing avidity, might suggest impaired response in
antibody production to these proteins following invasive pneumo-
coccaldisease. Conversely, since increasedantibody levels andavidity
are indicative of B-cellmemory response to an antigen, our data could
also imply a consumption of the antibody in the formation of
antibody–antigen complexes at the sites of infection. Also, an
inadequate antibody response might be related to the ability of high
doses of pneumococcal polysaccharides to depress the immune
systemaswell as deplete thememorypool. The relationship between
IL-10 and antibody productionmay be complicated.27 IL-10 has been
known to promote humoral immune responses. High levels of IL-10
have been associated with a suppression of the antibody response to
pneumococcus, which could explain the low antibodies observed
during theacutephaseof IPD,whenthe frequencyof IL-10-expressing
CD4+ T-cells was high as compared to healthy controls observed in
our study.28
Data in mice indicate that CD4+ T-cell interactions with
pneumococci are crucial in providing protection in the host.14
Further evidence for the role of CD4+ T-cells comes from the
increased risk of IPD in HIV-positive individuals with low CD4+ T-
cell counts.29 Our data show no variation in IFN-g production
following stimulation with pneumococcal antigens during the
acute or convalescent phases, suggesting a defect in the IFN-g
response could have rendered them vulnerable to invasive
pneumococcal disease, as previously described.30,31 The frequency
of T-cell responses expressing cytokines tomost antigens including
Figure 4. CD4+ production of interferon-gamma (IFN-g), interleukin-10 (IL-10), and tumor necrosis factor-alpha (TNF-a) at different stages of invasive pneumococcal disease
(IPD). The frequency (% CD4+ T-cells) of IFN-g-, IL-10-, and TNF-a-producing CD4+ T-cells was measured following overnight stimulation with either (D39) Streptococcus
pneumoniae strain (WT), recombinant pneumolysin (Ply), or phytohemagglutinin (PHA). The horizontal lines indicate the medians of n = 11 for acute phase, n = 6 for
convalescent (Conv) phase, and n = 16 for healthy controls; p-values indicate signiﬁcant differences between any of the two groups designated.
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adults.32,33 However, the lack of an IFN-g response to a non-
pneumococcal antigen such as PHA is an indication of a generalized
limitation of the IFN-g that could either be intrinsic to the host or
from reciprocal inhibition of the high IL-10 response.34,35 The role
of TNF-a in IPD is controversial. Our data show increased TNF-a
production during the acute phase that returns to normal during
convalescence, in keeping with its inﬂammatory role.
To the best of our knowledge, this study is the ﬁrst to measure
T-cell and antibody responses to pneumococcal proteins in
association with anti-capsular antibodies during IPD in children.
We have demonstrated low antibody concentrations and varia-
tions in CD4+ T-cell immune responses to pneumococcal protein
antigens; these do not provide conclusive evidence of their
protective role against IPD, as they might either be a cause or
consequence of the disease. Nevertheless, our data do indicate that
these antigens are expressed at sufﬁcient levels to be relevant to
the immune system, which warrants their further assessment as
potential vaccine candidates.
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